Precision Dosing Promises to Revolutionise Chronic Skin Disease Treatment

Biologic therapies—highly targeted drugs that modulate the immune system—are a game-changer for severe skin conditions like psoriasis and atopic dermatitis. However, their effectiveness is hampered by a major flaw: standardised dosing that ignores individual patient differences. This can lead to the treatment not working, losing its effect over time, or causing adverse reactions.

A new review highlights a paradigm shift away from this rigid approach towards a dynamic, predictive strategy called model-informed precision dosing (MIPD). Unlike older methods that simply react to drug levels in the blood, MIPD proactively uses sophisticated pharmacokinetic and pharmacodynamic modelling. By integrating population data with a patient's own biological profile and using forecasting techniques, it generates adaptive, individualised dosing recommendations.

This patient-centric approach, supported by digital health tools, promises to maximise clinical response, minimise toxicity, and make long-term treatment more sustainable and effective.